Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill aims to shrink spleens in bone marrow cancer patients

NCT ID NCT05020652

First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 22 times

Summary

This study tests a new tablet called TQ05105 against a standard drug, hydroxyurea, in people with moderate to high-risk myelofibrosis, a type of bone marrow cancer. The main goal is to see if TQ05105 can shrink the spleen by at least 35% after 24 weeks. About 107 adults aged 18-75 are taking part, and the study is currently active but not recruiting new participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE AND HIGH RISK MYELOFIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Guangdong Provincial Peoples Hospital

    Guangzhou, Guangdong, 510055, China

  • Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College

    Tianjin, Tianjin Municipality, 300020, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100005, China

  • West China School of Medicine / West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.